Weight loss treatment of COVID-19 in patients with NCDs: a pilot prospective clinical trial-Reference-Cited by-同舟云学术

Weight loss treatment of COVID-19 in patients with NCDs: a pilot prospective clinical trial

Published:2023-04-07 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Oshakbayev Kuat¹,Durmanova Aigul¹,Zhankalova Zulfiya¹,Idrisov Alisher²,Bedelbayeva Gulnara³,Gazaliyeva Meruyert²,Nabiyev Altay¹,Tordai Attila⁴,Dukenbayeva Bibazhar²

Affiliation:

1. University medical center

2. Astana Medical University

3. Kazakh National Medical University

4. Semmelweis University

Abstract

Abstract Background COVID-19 in comorbidity with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. Objective. To evaluate the effects of the weight loss treatment on clinic/laboratory inflammation and metabolic profile, reactive oxygen species (ROS) body composition in patients with COVID-19 in comorbidity with NCDs. Design: A 6-week open, pilot prospective clinical trial. Setting: The study included 72 adult patients with COVID and influenza in comorbidity with type 2 diabetes (T2D), hypertension, and NASH. Interventions: The treatment involved a fast-weight-loss-method (Analimentary detoxication, ANADETO) including calorie restriction to 50–100 kcal/day, salt intake to 5–6 gr/day, hot water drinking 1000–1500 ml/day, walking > 2,000 steps/day, and sexual self-restraint. Main outcome measures: Primary endpoints: Clinic/infectious/inflammation tests for COVID/Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT/AST, chest-CT-scan. Results The patients weight lost from baseline (-9,14 − 12,4%; P < 0.001); COVID and Influenza were a negative in > 96.3% patients at the 14 days. Systolic/diastolic BP normalized (P < 0.0001), glucose/lipids metabolism (P < 0.0001); ALT/AST normalized (P < 0.0001), platelets increased from baseline (P < 0.0001), chest-CT (P < 0.0001) at 6-week follow-up. The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2–5 days to completely stopping by 5–8 days treatment. Conclusions The non-pharmacological treatment including fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH. Trial Registration: ClinicalTrials.gov NCT05635539 (12/01/2022): https://clinicaltrials.gov/ct2/show/NCT05635539?term=NCT05635539&draw=2&rank=1 .

Publisher

Research Square Platform LLC

Reference73 articles.

1. Federation WO. Covid-19 and obesity: the 2021 atlas.March 2021.

2. Li CX, Noreen S, Zhang LX, Saeed M, Wu PF, Ijaz M, Dai DF, Maqbool I, Madni A, Akram F et al. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.Biomedicine & Pharmacotherapy2022,146.

3. Veronese N, Smith L, Di Gennaro F, Bruyere O, Yang L, Demurtas J, Maggi S, Sabico S, Al-Daghri NM, Barbagallo M et al. Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study.Vaccines2022,10.

4. Treatment outcomes of acute streptococcal tonsillitis according to antibiotic treatment. A retrospective analysis of 242,366 cases treated in the community;Bar-Yishay M;Eur J Gen Pract,2022

5. Rahman MM, Bibi S, Rahaman MS, Rahman F, Islam F, Khan MS, Hasan MM, Parvez A, Hossain MA, Maeesa SK et al. Natural therapeutics and nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology.Chemical Engineering Journal2022,446.